Kohli M - Search Results

1

Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines.

Thommes EW, Kruse M, Kohli M, Sharma R, Noorduyn SG. Thommes EW, et al. Among authors: kohli m. Hum Vaccin Immunother. 2017 Apr 3;13(4):867-876. doi: 10.1080/21645515.2016.1251537. Epub 2016 Nov 18. Hum Vaccin Immunother. 2017. PMID: 27858509 Free PMC article. Review.

2

The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom.

Kohli MA, Maschio M, Mould-Quevedo JF, Drummond M, Weinstein MC. Kohli MA, et al. Hum Vaccin Immunother. 2021 Nov 2;17(11):4603-4610. doi: 10.1080/21645515.2021.1971017. Epub 2021 Sep 22. Hum Vaccin Immunother. 2021. PMID: 34550848 Free PMC article.

3

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany.

Kohli MA, Maschio M, Cartier S, Mould-Quevedo J, Fricke FU. Kohli MA, et al. Vaccines (Basel). 2022 Aug 25;10(9):1386. doi: 10.3390/vaccines10091386. Vaccines (Basel). 2022. PMID: 36146464 Free PMC article.

4

Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France.

Lee A, Davido B, Beck E, Demont C, Joshi K, Kohli M, Maschio M, Uhart M, El Mouaddin N. Lee A, et al. Among authors: kohli m. Hum Vaccin Immunother. 2024 Dec 31;20(1):2423474. doi: 10.1080/21645515.2024.2423474. Epub 2024 Nov 14. Hum Vaccin Immunother. 2024. PMID: 39540209 Free PMC article.

5

Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada.

Kohli M, Attard C, Lam A, Huse D, Cook J, Bourgault C, Alemao E, Yin D, Marentette M. Kohli M, et al. Pharmacoeconomics. 2006;24(8):815-30. doi: 10.2165/00019053-200624080-00007. Pharmacoeconomics. 2006. PMID: 16898850

6

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.

Kohli M, Lawrence D, Haig J, Anonychuk A, Demarteau N. Kohli M, et al. BMC Public Health. 2012 Oct 13;12:872. doi: 10.1186/1471-2458-12-872. BMC Public Health. 2012. PMID: 23061913 Free PMC article.

7

Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion.

Kohli MA, Farkouh RA, Maschio MJ, McGarry LJ, Strutton DR, Weinstein MC. Kohli MA, et al. Health Aff (Millwood). 2015 Jul;34(7):1234-40. doi: 10.1377/hlthaff.2014.1274. Health Aff (Millwood). 2015. PMID: 26135209

8

The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom.

Kohli MA, Maschio M, Mould-Quevedo JF, Ashraf M, Drummond MF, Weinstein MC. Kohli MA, et al. Vaccines (Basel). 2021 Jun 4;9(6):598. doi: 10.3390/vaccines9060598. Vaccines (Basel). 2021. PMID: 34199912 Free PMC article.

9

An Economic Comparison of Influenza Vaccines Recommended for Use in Eligible Adults under 65 Years in the United Kingdom.

Maschio M, Kohli MA, Ashraf M, Drummond MF, Weinstein MC, Mould-Quevedo JF. Maschio M, et al. Among authors: kohli ma. Vaccines (Basel). 2022 Apr 13;10(4):599. doi: 10.3390/vaccines10040599. Vaccines (Basel). 2022. PMID: 35455348 Free PMC article.

10

The cost-effectiveness of screening blood donors for malaria by PCR.

Shehata N, Kohli M, Detsky A. Shehata N, et al. Among authors: kohli m. Transfusion. 2004 Feb;44(2):217-28. doi: 10.1111/j.1537-2995.2004.00644.x. Transfusion. 2004. PMID: 14962313

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

590 results

Search Page

Filters